Full-Time

Business Associate Program

Multiple Teams

Posted on 9/12/2025

Deadline 10/12/25
Wellington Management

Wellington Management

1,001-5,000 employees

Global asset management for institutional clients

No salary listed

No H1B Sponsorship

Boston, MA, USA

Hybrid

Hybrid work environment, allowing for 4 days in person and up to 20% of time working from home.

Category
Finance & Banking (3)
, ,
Required Skills
Word/Pages/Docs
Salesforce
Data Analysis
Excel/Numbers/Sheets
Financial Modeling
PowerPoint/Keynote/Slides
Requirements
  • Undergraduates from all majors graduating with a bachelor’s degree between Fall 2025 – Summer 2026
  • Demonstrated interest in investment management
  • Proficiency in Microsoft Office, specifically in Word, PowerPoint, and Excel
  • Demonstrated accomplishments in academics
  • Proven leadership experience and participation in community service and extracurricular activities
Responsibilities
  • Prepare presentation materials, briefing materials and other collateral materials for prospect calls and meetings as well as new business opportunities with existing clients
  • Organize prospect and client meeting follow-up items and respond to ad hoc requests, as needed
  • Qualify Requests for Proposal (RFPs) and work with internal constituents to ensure that each RFP receives the appropriate response
  • Assist with analytics and competitor analysis
  • Manage Salesforce to allow members of the Client Group to better coordinate client/prospect information and insights
  • Attend various internal cross functional meetings
  • Collaborate with members of the department to support external relationships with clients, prospects, and consultants
  • Work on ad-hoc projects to support our overall client effort
  • Ensure the books and records of assigned legal entities are maintained in accordance with GAAP
  • Assist with the preparation of financial statements in conjunction with annual audits
  • Prepare filings and surveys for a variety of regulatory agencies with adherence to strict deadlines
  • Recommending process improvements leveraging any technological expertise
  • Assist with daily cash management processes including payment execution, liquidity management, and forecasting
  • Perform analysis and trade execution related to foreign currency activities, hedging, and long-term investments
  • Prepare monthly and ad hoc reporting on hedging results, investments, and liquidity management
  • Assist with the annual budget and quarterly forecast updates, including work on the consolidated forecast model
  • Assist with monthly expense analysis for multiple divisions, including reporting and direct meetings with leadership
  • Assist with various projects related to financial modeling/strategic investments
  • Preparation of tax basis accounting work papers and other work papers supporting tax filings
  • Prepare quarterly estimated tax payment calculations and annual extensions
  • Monitor personal trading, gifts and entertainment, political contributions, conflicts of interest and other related areas for compliance with our Code of Ethics
  • Participate in our compliance and forensic testing program to determine the firm’s compliance with its policies and procedures
  • Assist in the preparation and filing of global regulatory and beneficial ownership filings
  • Partner with compliance officers and analysts on special projects supporting the compliance program
  • Support capital markets initiatives related to derivatives trading and private equity transactions
  • Assist the review and negotiation of investment management agreements to support our institutional client business
  • Partner with attorneys or analysts on special projects to support regulatory initiatives
Wellington Management

Wellington Management

View

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$60B

Headquarters

Boston, Massachusetts

Founded

1933

Simplify Jobs

Simplify's Take

What believers are saying

  • $1.19T AUM as of December 2024 supports scale across 50 countries.
  • Led Encord's $60M Series C to scale AI data platform in 2026.
  • Private credit market exceeds $30T, fueling 2023-launched capabilities.

What critics are saying

  • BlackRock's $11.5T AUM erodes active fees via ETF scale.
  • Renk's €300M blocked revenue writedowns 5.09% stake value.
  • Quince lawsuit triggers $50-100M liability on Series E investment.

What makes Wellington Management unique

  • Launched Absolute Return Global Equity Fund for market-neutral alpha in volatility.
  • Expanded private real estate credit platform in 2025 with Ravi S. Anand leading.
  • Manages $40B in alternatives across 40 funds for institutional clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Radio Intereconomía
Apr 14th, 2026
Wellington launches global market neutral fund to capture alpha in volatile environment

Wellington Management has launched the Wellington Absolute Return Global Equity Fund, a UCITS vehicle employing a global market neutral strategy aimed at generating returns above cash with limited exposure to traditional markets. The fund expands Wellington's liquid alternatives offering. The launch comes amid increased market volatility and reduced stability, positioning the fund to capture alpha in challenging conditions through its market-neutral approach to global equities.

AD HOC NEWS Portal Aktiengesellschaft
Apr 12th, 2026
Wellington buys 5% stake in Renk as $339M in delayed defence contracts weigh on cash flow

Wellington Management has acquired a 5.09% stake in German defence supplier Renk Group, signalling confidence despite the company facing significant operational challenges. The US asset manager built its position through direct share purchases and equity swaps. Renk is currently contending with approximately €300 million in blocked revenue due to delayed deliveries and missing export licenses. Around €200 million in planned sales has been pushed to 2026, whilst €80-100 million in orders for Israeli tank gearbox systems await German export approval. The cash flow pressure is evident, with free cash flow reaching only €67 million last fiscal year, well below the company's 80% conversion target. Shares fell 4.34% to €52.05, extending year-to-date losses to nearly 6%. Despite near-term challenges, Renk maintains a record order backlog of €6.68 billion.

Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Business Wire
Apr 2nd, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...

医谷网
Mar 23rd, 2026
London gene therapy firm NightstaRx raises $45M to advance blindness treatment trials

NightstaRx, a London-based ophthalmology company developing gene therapies for inherited retinal diseases, has raised $45 million in Series C funding. Wellington Management Company and Redmile Group led the round, with participation from existing investors Syncona and New Enterprise Associates. Founded in 2013, Nightstar has four drug candidates targeting conditions including choroideremia, X-linked retinitis pigmentosa and macular degeneration. Its lead candidate, NSR AAV-REP1, uses an adeno-associated virus vector to deliver the REP-1 gene to retinal cells, potentially offering a one-time treatment for choroideremia, which causes progressive blindness. The therapy is currently in phase 1/2 trials, with positive results from 14 patients published in The Lancet. The funding will advance NSR AAV-REP1 into phase 3 trials and progress two other candidates into phase 1/2 studies.

INACTIVE